Surface-modified vacuole-based daunorubicin delivery system for acute myeloid leukaemia (AML) and their selective therapeutics

IF 4.5 3区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Artificial Cells, Nanomedicine, and Biotechnology Pub Date : 2022-05-30 DOI:10.1080/21691401.2022.2078339

Wooil Choi, Yang-Hoon Kim, Jiho Min

{"title":"Surface-modified vacuole-based daunorubicin delivery system for acute myeloid leukaemia (AML) and their selective therapeutics","authors":"Wooil Choi, Yang-Hoon Kim, Jiho Min","doi":"10.1080/21691401.2022.2078339","DOIUrl":null,"url":null,"abstract":"Abstract The vacuoles in Saccharomyces cerevisiae are the key players digesting the waste within the cell. This functional organelle corresponding to the lysosome of mammalians contains acidic hydrolases and specific membrane proteins. Vacuoles have more than 60 hydrolytic enzymes and can easily be modified by genetic engineering. In previous study, we optimised the encapsulation condition with appropriate time and concentration and confirmed the use of vacuole as drug delivery carrier for acute myeloid leukaemia treatment. In this study, recombinant vacuole that could target the acute myeloid leukaemia cell line was constructed. The vacuoles derived from genetic engineered yeast were decorated with targeting peptide that has specific affinity with TLR2 on AML cell membrane. The anti-cancer efficacy of AML targeting vacuoles carriers with encapsulated daunorubicin was shown to be higher than normal vacuole carriers and the crude daunorubicin. The results confirmed that target selective chemotherapy using the vacuole drug delivery system is effective and offers potential for cancer therapy.","PeriodicalId":8736,"journal":{"name":"Artificial Cells, Nanomedicine, and Biotechnology","volume":"90 1","pages":"147 - 157"},"PeriodicalIF":4.5000,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artificial Cells, Nanomedicine, and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/21691401.2022.2078339","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 7

Abstract

Abstract The vacuoles in Saccharomyces cerevisiae are the key players digesting the waste within the cell. This functional organelle corresponding to the lysosome of mammalians contains acidic hydrolases and specific membrane proteins. Vacuoles have more than 60 hydrolytic enzymes and can easily be modified by genetic engineering. In previous study, we optimised the encapsulation condition with appropriate time and concentration and confirmed the use of vacuole as drug delivery carrier for acute myeloid leukaemia treatment. In this study, recombinant vacuole that could target the acute myeloid leukaemia cell line was constructed. The vacuoles derived from genetic engineered yeast were decorated with targeting peptide that has specific affinity with TLR2 on AML cell membrane. The anti-cancer efficacy of AML targeting vacuoles carriers with encapsulated daunorubicin was shown to be higher than normal vacuole carriers and the crude daunorubicin. The results confirmed that target selective chemotherapy using the vacuole drug delivery system is effective and offers potential for cancer therapy.

查看原文本刊更多论文

表面修饰的基于液泡的柔红霉素给药系统治疗急性髓性白血病及其选择性治疗

摘要酿酒酵母的液泡是细胞内消化废物的关键器官。这种功能细胞器与哺乳动物的溶酶体相对应，含有酸性水解酶和特定的膜蛋白。液泡具有60多种水解酶，可以很容易地通过基因工程进行修饰。在前期的研究中，我们优化了包封条件，选择合适的时间和浓度，确定了液泡作为药物递送载体用于治疗急性髓系白血病。本研究构建了靶向急性髓系白血病细胞系的重组液泡。利用基因工程酵母制备的液泡，在AML细胞膜上修饰与TLR2具有特异性亲和力的靶向肽。用柔红霉素包封的AML靶液泡载体的抗癌效果高于普通液泡载体和粗制柔红霉素。结果证实了利用液泡给药系统靶向选择性化疗是有效的，并为癌症治疗提供了潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Artificial Cells, Nanomedicine, and Biotechnology BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ENGINEERING, BIOMEDICAL

CiteScore

10.90

自引率

0.00%

发文量

审稿时长

20 weeks

期刊介绍： Artificial Cells, Nanomedicine and Biotechnology covers the frontiers of interdisciplinary research and application, combining artificial cells, nanotechnology, nanobiotechnology, biotechnology, molecular biology, bioencapsulation, novel carriers, stem cells and tissue engineering. Emphasis is on basic research, applied research, and clinical and industrial applications of the following topics:artificial cellsblood substitutes and oxygen therapeuticsnanotechnology, nanobiotecnology, nanomedicinetissue engineeringstem cellsbioencapsulationmicroencapsulation and nanoencapsulationmicroparticles and nanoparticlesliposomescell therapy and gene therapyenzyme therapydrug delivery systemsbiodegradable and biocompatible polymers for scaffolds and carriersbiosensorsimmobilized enzymes and their usesother biotechnological and nanobiotechnological approachesRapid progress in modern research cannot be carried out in isolation and is based on the combined use of the different novel approaches. The interdisciplinary research involving novel approaches, as discussed above, has revolutionized this field resulting in rapid developments. This journal serves to bring these different, modern and futuristic approaches together for the academic, clinical and industrial communities to allow for even greater developments of this highly interdisciplinary area.